1. What data in particular will be shared?
   Response - All of the individual participant data collected during the trial, after de-identification.
   


2. What additional supporting information will be shared?
   Response -  Study Protocol
   
   
3. Who will be able to view these files?
   Response - Researchers whose proposed use of the data has been approved by an independent review committee identified for this purpose.
   


4. For what types of analyses will this data be available?
   Response - To achieve aims in the approved proposal.
   


5. By what mechanism will data be made available?
   Response (Others) -  Data will be available at google and icloud. link will be generated after completion of study and data deidentification. Data will be available to those requestors who will sign a data access agreement.


6. For how long will this data be available start date provided 01-06-2026 and end date provided 01-06-2031?
   Response - Immediately following publication. No end date.
   


7. Any URL or additional information regarding plan/policy for sharing IPD? 
   Additional Information - NIL

Schizophrenia, a disabling mental disorder is characterized by cluster of both negative and positive symptoms. The positive symptoms are characterized by delusions, hallucinations and disorganization in thinking and behaviour. The negative symptoms refer to reduction of normal behaviour in the form of avolition, anhedonia, asociality, affective flattening and alogia. Whereas, the positive symptoms respond better to the available antipsychotic medications, the response of these medications in negative symptoms are meagre. There is also concern that negative symptoms run a chronic progressive course that leads to overall poor outcomes in the patient’s personal, social and occupational domains.

A recent study has shown that dysconnectivity between dorsolateral prefrontal cortex to cerebellum network directly corresponds to negative symptom severity. Another study involving 260 individuals with negative symptoms supported the evidence that reduced connectivity between the cerebellar-prefrontal network is associated with negative symptoms.

In recent researches, various non-invasive cerebellar stimulation at the vermis has shown to improve the negative symptoms of schizophrenia by improving the connectivity between the cerebellum and the prefrontal cortex. A systematic review further adds on to the evidence to positive outcomes of cerebellar stimulation. Amongst various NIBS techniques, most studied techniques are repeated transcranial magnetic stimulation (rTMS) and theta burst stimulation at cerebellum.

Indeed, some researchers have already used transcranial Direct Current Stimulation (tDCS) as a treatment for schizophrenia, evaluating effects over its common positive and negative symptoms. tDCS is a NIBS technique where direct current in the range of 0.5 to 2 mA is passed through the scalp by means of electrodes over designated areas of interest with an aim is to modulate the activity of specific brain region. Till date there is only 01 descriptive study including 04 patients investigating the effects of anodal tDCS over the cerebellum and primary motor cortex in schizophrenic patients suffering from tardive dyskinesia, also found that showed significant decrease in negative symptoms. Additionally, tDCS is considered one of the safe office procedures with minimal and self-limiting side-effects viz. burning sensation, redness at electrode placement area, tingling sensation, itching and headache.

Despite multiple benefits of this non-invasive treatment modality, there is a huge research gap in this field. Hence, this study proposes to study the effect of adjuvant Cerebellar anodal tDCS on Negative Symptoms of Schizophrenia